Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,184.40up ₹8.90 (0.76%)BSE ₹1,186.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,175.50.
29 Oct: open ₹1,175.50, high ₹1,187.80, low ₹1,170.50
52-week range of traded prices to 29 Oct 2026
₹835.50Low, 2 Apr 2026₹1,232.10High, 29 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,18,144 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.18
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 23.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.36
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,55,85055.6% delivered
Zydus Lifesciences shareholding disclosures
27 filed, newest first.
May 2026
Apr 2026
Aug 2025
Jun 2025
Apr 2024
Apr 2023
Apr 2022
Apr 2021
May 2020
18 May · Disclosure
Apr 2019
Apr 2018
Apr 2017
10 Apr · Disclosure
Apr 2016
Mar 2015
Dec 2014
Jan 2014
Jul 2013
Jun 2008
20 Jun · Disclosure
They propose to acquire 90,000,000 shares aggregating to 71.648% of the shares/voting rights of Cadila Healthcare Limited from Zydus Family Trust which holds 72% stake in Cadila Healthcare Limited. The mode of proposed acquisition is by way of inter-se-transfer and the date of proposed acquisition is June 27, 2008. The proposed acquisition price per share is Rs.2.077 per share at cost. The shareholding of Zydus Hospitals And Medical Research Private Limited after the proposed acquisition would be 90,000,000 shares aggregating to 71.648% of the shares/voting rights of Cadila Healthcare Limited.